Journal: Journal of Translational Autoimmunity

Article Title: Anti-IgLON5 encephalitis is associated with anti-retinal immunological reactivity without retinal alteration

doi: 10.1016/j.jtauto.2026.100359

Figure Lengend Snippet: Indirect immunofluorescence on sections of monkey retina. The fluorescence observed is identified by a black arrow. (A) Patient 4 (IgG4); (B) Patient 1 (IgG4); (C) Patient 3 (IgG1); (D) Patient 5 (IgG4); (E) Patient 2 (IgG1); (F) Patient 1 (IgG4) after immunoadsorption of IgLON5 antibodies; (G) Control with macular edema (IgG1); (H) Control with anti-Hu encephalitis (IgG1); (I) Control with CAR syndrome (IgG4). The different layers of the retina are identified by their initials: pigment epithelium (pe), photoreceptor layer (pr), outer grain layer (og), outer plexiform layer (op), inner grain layer (ig), inner plexiform layer (ip), ganglion cell layer (gc), nerve fibre layer (nf).

Article Snippet: The reactivity of the patients’ sera and/or CSF against the retina was evaluated retrospectively with frozen samples (−80°, EXPLAINEUR biobank) through an indirect immunofluorescence technique using sections of monkey retina (Ref. FA1172-1005, Euroimmun), detected with an FITC-labelled secondary antibody anti-human IgAGM (Euroimmun conjugate) or directed against IgA (ref. F0204, DAKO), IgM (ref. F0203, DAKO), IgG1 (ref. 9052-02, Southern Biotech) and IgG4 (ref. 9200-02, Southern Biotech).

Techniques: Immunofluorescence, Fluorescence, Control

Journal: BMC Cancer

Article Title: Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC

doi: 10.1186/s12885-026-16172-2

Figure Lengend Snippet: Expression of EpCAM on cell lines of SCC-UADT, HNSCC-associated fibroblasts, and normal fibroblasts. A Representative histogram and quantitative data on the percentage of EpCAM-positive cells as well as on the expression level of EpCAM of the SCC-UADT cell lines KYSE-30 (ESCC) and FaDu (HNSCC), the HNSCC-associated fibroblast cell line CAF-4, and the normal fibroblast cell line HFF-1 as assessed by flow cytometry upon immunostaining with the AlexaFluor488-labeled anti-EpCAM antibody VU1D9 (high EpCAM-affinity) (mean ± SEM for n = 4; * p < .05 vs. CAF; # p < .05 vs. HFF; § p < .05 vs. KYSE-30; & p < .05 vs. FaDu). B Representative histogram and quantitative data on the percentage of EpCAM-positive cells as well as on the expression level of EpCAM of the SCC-UADT cell lines KYSE-30 and FaDu, the HNSCC-associated fibroblast cell line CAF-4, and the normal fibroblast cell line HFF-1 as assessed by flow cytometry upon immunostaining with the AlexaFluor488-labeled anti-EpCAM antibody MT201 (intermediate EpCAM-affinity; clinically validated) (mean ± SEM for n = 4; * p < .05 vs. CAF; # p < .05 vs. HFF; § p < .05 vs. KYSE-30; & p < .05 vs. FaDu)

Article Snippet: In contrast, the monoclonal human anti-human IgG1 antibody MT201 (adecatumumab), exhibiting an intermediate binding affinity for EpCAM, has been developed by the company Micromet Inc. to generate a therapeutic anti-EpCAM antibody with a favorable toxicity profile, which has been successfully utilized in clinical studies [ , ].

Techniques: Expressing, Flow Cytometry, Immunostaining, Labeling

Journal: BMC Cancer

Article Title: Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC

doi: 10.1186/s12885-026-16172-2

Figure Lengend Snippet: A , B Representative multi-color epifluorescence microscopy images of immunohistochemically stained cryo-sections of bicellular core-shell-spheroids of HNSCC (FaDu; shell) and HNSCC-associated fibroblasts (CAF-4; core) illustrating the expression of EpCAM (red), S100A4/fibroblasts (green), DAPI/DNA (blue; scale bar: 200 μm; white dashed line: border FaDu/CAF-4) as well as quantitative data on the mean fluorescence intensity of the immunostaining with the IRDye800CW-labeled anti-EpCAM antibody VU1D9 ( A ) or MT201 ( B ) or the respective control antibodies in the HNSCC shell as well as the HNSCC-associated fibroblast core (CAF-4) (mean ± SEM for n = 3; * p < .05 vs. isotype ctrl (CAF4); # p < .05 vs. isotype ctrl (FaDu); § p < .05 vs. VU1D9 (CAF4) or MT201 (CAF4) ; & p < .05 VU1D9 (FaDu) or MT201 (FaDu)). C , D Representative multi-color epifluorescence microscopy images of immunohistochemically stained cryo-sections of bicellular core-shell-spheroids of ESCC (KYSE-30; shell) and HNSCC-associated fibroblasts (CAF-4; core) illustrating the expression of EpCAM (red), S100A4/fibroblasts (green), DAPI/DNA (blue; scale bar: 200 μm; white dashed line: border KYSE-30/CAF-4) as well as quantitative data on the mean fluorescence intensity of the immunostaining with the IRDye800CW-labeled anti-EpCAM antibody VU1D9 ( C ) or MT201 ( D ) or the respective control antibodies in the ESCC shell as well as the HNSCC-associated fibroblast core (CAF-4) (mean ± SEM for n = 3; * p < .05 vs. isotype ctrl (CAF4); # p < .05 vs. isotype ctrl (KYSE-30); § p < .05 vs. VU1D9 (CAF4) or MT201 (CAF4) ; & p < .05 VU1D9 (KYSE-30) or MT201 (KYSE-30))

Article Snippet: In contrast, the monoclonal human anti-human IgG1 antibody MT201 (adecatumumab), exhibiting an intermediate binding affinity for EpCAM, has been developed by the company Micromet Inc. to generate a therapeutic anti-EpCAM antibody with a favorable toxicity profile, which has been successfully utilized in clinical studies [ , ].

Techniques: Epifluorescence Microscopy, Staining, Expressing, Fluorescence, Immunostaining, Labeling, Control

Journal: BMC Cancer

Article Title: Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC

doi: 10.1186/s12885-026-16172-2

Figure Lengend Snippet: EpCAM expression in HNSCC, non-malignant HNSCC-associated and non-HNSCC-associated stroma, as well as non-malignant mucosa in cryosections of patient tissue samples with primary and recurrent HNSCC. A , B Representative light microscopy images (overview, scale bar: 200 μm; right: details, scale bar: 60 μm) of immunohistochemically stained HNSCC tissue (hematoxylin staining of nuclei; anti-EpCAM-antibody VU1D9: red) as well as quantitative data on the percentage of EpCAM-positive HNSCC tissue of all the HNSCC tissue visible in the patient tissue samples with primary ( A ) and recurrent ( B ) HNSCC ( n = 9 per group) upon immunohistochemical EpCAM / hematoxylin staining. Quantitative data is illustrated as absolute expression percentages (i) of the single patient samples as bar chart and (ii) grouped as pie chart (expression percentage 0–19%: blue; 20–79%: green; 80–100%: red). C-F Representative multi-color epifluorescence microscopy images of immunohistochemically stained additional cryosections of the same tissue samples of HNSCC and of non-malignant mucosa illustrating the expression of EpCAM (red) and DAPI/DNA (blue; scale bar: 100 μm) as well as quantitative data on the relative background-corrected mean fluorescence intensity levels of selected regions of interest (HNSCC, non-malignant mucosa, HNSCC-associated stroma, and non-HNSCC-associated stroma (subepithelial)) as assessed by anti-EpCAM antibody immunostaining with the antibody VU1D9 ( C/E ) and MT201 ( D/F ) in tissue samples of patients with primary ( C/D ) and recurrent ( E/F ) HNSCC (mean ± SEM for n = 9; * p < .05 vs. HNSCC)

Article Snippet: In contrast, the monoclonal human anti-human IgG1 antibody MT201 (adecatumumab), exhibiting an intermediate binding affinity for EpCAM, has been developed by the company Micromet Inc. to generate a therapeutic anti-EpCAM antibody with a favorable toxicity profile, which has been successfully utilized in clinical studies [ , ].

Techniques: Expressing, Light Microscopy, Staining, Immunohistochemical staining, Epifluorescence Microscopy, Fluorescence, Immunostaining

Journal: BMC Cancer

Article Title: Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC

doi: 10.1186/s12885-026-16172-2

Figure Lengend Snippet: Postoperative immunostaining of live intraoperatively harvested and cultured patient samples with the IRDye800CW-labeled anti-EpCAM-antibody MT201 (adecatumumab) for fluorescence-based differentiation of HNSCC, non-malignant mucosa, and non-malignant HNSCC-associated stroma. A Representative multi-color confocal laserscanning microscopy images of live intraoperatively harvested and postoperatively immunostained paired tissue sample of HNSCC and non-malignant mucosa (DAPI/DNA: blue; CellMask Green/cell membranes: green; MT201/EpCAM: red; Corresponding H&E staining: multicolor; scale bar: 100 μm) as well as ( B) quantitative data on the relative background-corrected mean fluorescence intensity levels of selected regions of interest (HNSCC, non-malignant mucosa, and non-malignant HNSCC-associated stroma) as assessed by immunostaining with the anti-EpCAM antibody MT201 (adecatumumab) in tissue samples of patients with primary and recurrent HNSCC (mean ± SEM for n = 12; * p < .05 vs. HNSCC)

Article Snippet: In contrast, the monoclonal human anti-human IgG1 antibody MT201 (adecatumumab), exhibiting an intermediate binding affinity for EpCAM, has been developed by the company Micromet Inc. to generate a therapeutic anti-EpCAM antibody with a favorable toxicity profile, which has been successfully utilized in clinical studies [ , ].

Techniques: Immunostaining, Cell Culture, Labeling, Fluorescence, Microscopy, Staining